Who Are the Core Customers of Molecular Data Company?

R&D labs and procurement managers at small and mid-sized pharma and biotech firms rely on Molbase for rapid sourcing of reagents and building blocks from a catalog exceeding 70 million compounds by 2025, cutting lead times and purchase friction for drug discovery and formulation work.

Secondary distributors and mid-tier manufacturers use Molbase as a back-end supply chain tool, leveraging its logistics and warehousing data to manage local inventories and spot purchases, supporting faster fulfillment and lower working capital needs.

Molbase primarily serves business customers (B2B): biotech and pharma clients, contract research organizations (CROs), and clinical diagnostics companies, plus a growing number of academic research institutions using the platform for procurement and sourcing rare reagents.

By 2025 the commercially most important segment is mid-sized R&D-focused biotech and pharma firms-these customers account for the bulk of transactions and rely on Molbase for catalog depth (70M+ compounds) and spot-market pricing transparency; see related context in Mission, Vision, and Values of Molecular Data Company.

Asia-Pacific, with China accounting for over 40% of global chemical output, is the primary market for molecular data company customers because manufacturers and suppliers need sourcing, specs, and regulatory data at scale. Industrial buyers and domestic pharma clusters in China drive the largest transaction volume.

Vietnam and India are rising Plus One manufacturing hubs where emerging pharmaceutical clusters rely on molecular data services for cross-border sourcing and compliance; US-based biotech startups form another strong segment, using the Knowledge Base to source rare building blocks for AI-driven drug modeling.

Molbase shows greatest reach in supply-chain-heavy sectors-chemicals, specialty materials, and pharma-reflected in a revenue mix where trade and sourcing services represent a majority of transactions; usage is highest among contract manufacturers and chemical distributors in APAC.

New Energy-specifically lithium-ion battery precursors and specialty electrolytes-became a high-growth channel in 2025-2026, accounting for a significant share of new transaction volume. Clinical diagnostics companies and precision medicine startups are also increasing purchases of genomic and molecular datasets.

Molbase moves beyond transactional users by offering AI market intelligence and analytics, drawing biotech and pharma clients, academic research institutions, and precision medicine companies. In 2025 the firm reported a 38% rise in enterprise subscriptions for data services, and in early 2026 it began piloting chemical-hedging tools for financial desks in CPG and specialty-chem firms.

Core customers-procurement officers and contract research organizations-retain access to the marketplace and basic listings with verified molecular records. Molbase enforces data accuracy via ongoing quality inspection services and real-time logistics tracking, keeping transactional friction low and churn under 6% for 2025 enterprise accounts.

Layered services encourage repeat demand from pharma companies purchasing molecular data and clinical labs buying genomic data services; annual renewals rose to 82% in 2025. Integration into procurement workflows and analytics dashboards increases daily active usage among drug discovery teams and diagnostic test developers.

The key growth lever is vertical deepening-adding adjacent financial derivatives for chemical hedging and logistics while preserving the molecular database as the single source of truth. This kept average revenue per user up 27% in 2025 and enabled Molbase to position itself as an indispensable utility for biotech investors evaluating molecular data company clients and hospital systems using molecular data providers.